



FOR IMMEDIATE RELEASE

Amneal Launches Tiagabine Hydrochloride Tablets, Generic for Gabitril®

Bridgewater, NJ (USA), March 12, 2018 - [Amneal Pharmaceuticals](http://www.amneal.com) has launched tiagabine hydrochloride tablets in 2 mg, 4 mg, 12 mg and 16 mg strengths. The product is an AB-rated therapeutic equivalent for Gabitril®.

Tiagabine HCl tablets, available in a 30-ct bottles, are now shipping to wholesalers, distributors and direct to the trade.

Annual U.S. sales of Gabitril® and its generic equivalents were \$30 million, according to January 2018 IQVIA™ market data.

About Amneal

Amneal Pharmaceuticals LLC, a privately-held company headquartered in Bridgewater, New Jersey, is one of the largest and the fastest growing generics pharmaceutical manufacturers in the United States. Founded in 2002, Amneal now has more than 5,000 employees in North America, Asia and Europe, working together to bring high quality affordable medicines to patients worldwide. Amneal has significantly expanded its portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas.

Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. (NASDAQ: IPXL) announced on October 17, 2017 that they have entered into a definitive business combination agreement with the resulting combined company expected to create the 5th largest generics business (by gross revenue) in the United States. The transaction is expected to close in the first half of 2018.

For more information, visit [amneal.com](http://www.amneal.com).

All trademarks listed in this release are property of their respective owners.
Product photo is available upon request.

###

CONTACTS:

Sales

Andy Boyer
Executive Vice President, Commercial Operations
908.409.6891
andy.boyer@amneal.com

Media

Cheryl Lechok
Media Relations
203.613.1506
mediarelations@amneal.com

Business Development

Apurva Saraf
Vice President, Global Strategy & Corporate
Development
631.742.7674
apurvas@amneal.com